Randomized-controlled trials in people at ultra high risk of psychosis: A review of treatment effectiveness

Schizophrenia Research

Volumn 123, Issue 1, 2010, Pages 30-36

  Preti, Antonio ^a   Cella, Matteo ^b  

^a Centro Medico Genneruxi   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Early intervention; High risk; Meta analysis; Randomized controlled trial; Schizophrenia

Indexed keywords

OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; RISPERIDONE;

CLINICAL TRIAL; COGNITIVE THERAPY; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; EARLY INTERVENTION; FAMILY COUNSELING; FAMILY THERAPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MEDLINE; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79959896923     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.07.026     Document Type: Review

References (56)

1. Amminger G.P., Schäfer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
2. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 1994, APA (American Psychiatric Association), American Psychiatric Association Press, Washington, DC. Fourth Edition.
3. Bechdolf A., Wagner M., Veith V., et al. A randomized controlled multicenter trial of cognitive behaviour therapy in the early initial prodromal state of psychosis. Schizophr. Res. 2006, 86:S8.
4. Bechdolf A., Wagner M., Veith V., et al. Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv. Psychiatry 2007, 1:71-78.
5. Bechdolf A., Wagner M., Ruhrmann S., et al. CBT in the early initial prodromal state: 24-months results. Schizophr. Res. 2008, 102:S33.
6. Carson K.P., Schriesheim C.A., Kinicki A.J. The usefulness of the "fail-safe" statistic in meta-analysis. Educ. Psychol. Meas. 1990, 50:233-243.
7. Cocchi A., Meneghelli A., Preti A. "Programma 2000": celebrating ten years of activity of an Italian pilot program on early intervention in psychosis. Aust. N. Z. J. Psychiatry 2008, 42:1003-1012.
8. Corcoran C., Malaspina D., Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr. Res. 2005, 73:173-184.
9. Corcoran C.M., First M.B., Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr. Res. 2010, 120:16-22.
10. Cornblatt B.A., Lencz T., Smith C.W., et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry 2007, 68:546-557.
11. de Koning M.B., Bloemen O.J.N., van Amelsvoort T.A.M.J., et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr. Scand. 2009, 119:426-442.
12. Duval S., Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J. Am. Stat. Ass. 2000, 95:89-98.
13. Duval S., Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
14. Edwards J., McGorry P.D. Implementing Early Intervention in Psychosis. A Guide to Establishing Early Psychosis Services 2002, Dunitz, London, UK.
15. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
16. Fusar-Poli P., Valmaggia L., McGuire P. Can antidepressants prevent psychosis?. Lancet 2007, 370:1746-1748.
17. Gross G. The onset of schizophrenia. Schizophr. Res. 1997, 28:187-198.
18. Haddad P.M., Dursun S.M. Neurological complications of psychiatric drugs: clinical features and management. Hum. Psychopharmacol. 2008, 23(Suppl 1):15-26.
19. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
20. Huber G., Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog. Med. 1989, 80:646-652.
21. Huber G., Gross G., Schüttler R. Schizophrenie. Eine Verlaufsund sozialpsychiatrische Langzeitstudie 1979, Springer, Berlin, Germany.
22. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opin. Drug Discov. Dev. 2009, 12:468-478.
23. Jenkins J.H., Carpenter-Song E.A. Awareness of stigma among persons with schizophrenia: marking the contexts of lived experience. J. Nerv. Ment. Dis. 2009, 197:520-529.
24. Klosterkötter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry 2001, 58:158-164.
25. Klosterkötter J., Ruhrmann S., Schultze-Lutter F., et al. The European prediction of psychosis study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005, 4:161-167.
26. Larsen T.K., Friis S., Haahr U., et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr. Scand. 2001, 103:323-334.
27. Lipsey M.W., Wilson D.B. Practical Meta-analysis 2001, Sage Publications.
28. Marshall M., Rathbone J. Early Intervention for Psychosis. Cochrane Database Syst. Rev. 2006, CD004718.
29. McGlashan T.H., Zipursky R.B., Perkins D., et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis, I: study rationale and design. Schizophr. Res. 2003, 61:7-18.
30. McGlashan T.H., Zipursky R.B., Perkins D., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006, 163:790-799.
31. McGorry P.D. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am. J. Psychiatry 2007, 164:859-860.
32. McGorry P.D., Yung A.R., Phillips L.J., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
33. McGorry P.D., Nelson B., Amminger G.P., et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009, 70:1206-1212.
34. Miller T.J., Mcglashan T.H., Rosen J.L., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29:703-715.
35. Morrison A.P., French P., Walford L., et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br. J. Psychiatry 2004, 185:291-297.
36. Morrison A.P., French P., Parker S., et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 2007, 33:682-687.
37. Nordentoft M., Thorup A., Petersen L., et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006, 83:29-40.
38. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?. Curr. Drug Saf. 2009, 4:84-93.
39. Olsen K.A., Rosenbaum B. Prospective investigation of the prodromal state of schizophrenia: review of studies. Acta Psychiatr. Scand. 2006, 113:247-272.
40. Phillips L.J., McGorry P.D., Yuen H.P., Ward J., Donovan K., Kelly D. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res. 2007, 96:25-33.
41. Raballo A., Larøi F. Clinical staging: a new scenario for the treatment of psychosis. Lancet 2009, 374:365-367.
42. Raballo, A., Sæbye, D., Parnas, J., 2009. Looking at the schizophrenia spectrum through the prism of self-disorders: an empirical study. Schizophr. Bull. Jun 15. [Epub ahead of print]. http://doi:10.1093/schbul/sbp056.
43. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol. Bull. 1979, 86:638-641.
44. Ruhrmann S., Bechdolf A., Kühn K.U., et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br. J. Psychiatry 2007, 51(Suppl):S88-S95. LIPS study group.
45. Ruhrmann S., Schultze-Lutter F., Klosterkötter J. Probably at-risk, but certainly ill - advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr. Res. 2010, 120:23-37.
46. Ruhrmann S., Schultze-Lutter F., Salokangas R.K., et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 2010, 67:241-251.
47. Schulz, K.F., Altman, D.G., Moher, D., CONSORT Group, 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 152, 726-732.
48. Smith M.L., Glass G.V. Meta-analysis of psychotherapy outcome studies. Am. Psychol. 1977, 32:752-760.
49. Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10) 1992, WHO (World Health Organization), WHO Press, Geneve.
50. Yang L.H., Wonpat-Borja A.J., Opler M.G., Corcoran C.M. Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr. Res. 2010, 120:42-48.
51. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 1996, 22:353-370.
52. Yung A.R., Phillips L.J., Yuen H.P., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60:21-32.
53. Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004, 67:131-142.
54. Yung A.R., Yuen H.P., McGorry P.D., et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39:964-971.
55. Yung A.R., Nelson B., Stanford C., et al. Validation of prodromal criteria to detect individuals at ultra high risk of psychosis: 2year follow-up. Schizophr. Res. 2008, 105:10-17.
56. Yung A.R., Nelson B., Thompson A., Wood S.J. The psychosis threshold in Ultra High Risk (prodromal) research: is it valid?. Schizophr. Res. 2010, 120:1-6.